| GTO ID | GTC3496 |
| Trial ID | NCT05929716 |
| Disease | Large B-Cell Lymphoma | B-Cell Lymphoma |
| Therapy | CAR-T cell |
| Treatment | CAR-T cells |
| Phase | Phase2 |
| Recruitment status | Not Recruiting |
| Title | An Open-Label, Single Center Phase 2 Study of Magrolimab, Rituximab and Radiation as Bridging Strategy Before CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphoma |
| Year | 2023 |
| Country | United States |
| Company sponsor | M.D. Anderson Cancer Center |
| Other ID(s) | 2022-1011|NCI-2023-05051 |
| Cohort 1 | |||||||
|
|||||||